PROTAC development gains momentum, but clinical performance is poor
Pharmaceutical Technology
FEBRUARY 13, 2023
This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections.
59 
Let's personalize your content